Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17267078 | 1.00 | SHBG (0.30) | SHBGMEN1KMT2A | |
| SCHEMBL12671470 | 0.88 | — | — | |
| SCHEMBL4173310 | 0.85 | ALDH1A1 (0.32) | — | |
| SCHEMBL30400959 | 0.85 | ALDH1A1 (0.32) | — | |
| SCHEMBL2380317 | 0.83 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL6253583 | 0.83 | — | — | |
| SCHEMBL2380320 | 0.83 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL2381805 | 0.83 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL6253588 | 0.83 | — | — | |
| SCHEMBL2380315 | 0.83 | MEN1 (0.32) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017022861-A1 | SUBSTITUTED GUANIDINE DERIVATIVE | 宇部興産株式会社 | 2017-02-09 | — | — | WO | disclosed |
| US-20150203890-A1 | PRODUCTION OF SIALYLATED N-GLYCANS IN LOWER EUKARYOTES | GLYCOFI INC (US) | 2015-07-23 | — | — | US | disclosed |
| WO-2014179765-A2 | NOVEL HUMAN MIRNAS FOR USE IN DIAGNOSIS, PROGNOSIS AND THERAPY OF HUMAN CONDITIONS AND DISEASES | THOMAS JEFFERSON UNIVERSITY (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20120115906-A1 | DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
| US-20100292249-A1 | MANUFACTURE OF RIMCAZOLE | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-11-18 | — | — | US | disclosed |
| US-7229813-B2 | Everninomicin biosynthetic proteins | SCHERING CORPORATION (US) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292249-A1 | MANUFACTURE OF RIMCAZOLE | P2RX5, CYP3A5, ADRA2C | SHBG 4772/4885MEN1 3330/4885KMT2A 4048/4885 |
| US-20120115906-A1 | DERIVATIVES OF 3-ALKOXY-4,5-DIARYLTHIOPHENE-2-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | HRH4, HCRTR1, NR3C1 | SHBG 1570/4885MEN1 1475/4885KMT2A 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.